WCG Wealth Advisors LLC Buys 4,295 Shares of Pfizer Inc. (NYSE:PFE)

WCG Wealth Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,347 shares of the biopharmaceutical company’s stock after buying an additional 4,295 shares during the period. WCG Wealth Advisors LLC’s holdings in Pfizer were worth $905,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new position in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer during the 2nd quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.3 %

NYSE:PFE opened at $29.67 on Friday. The firm has a market capitalization of $168.13 billion, a price-to-earnings ratio of -494.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.11. The stock’s 50 day moving average price is $29.35 and its two-hundred day moving average price is $28.20. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 EPS. Equities research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were paid a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.66%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.